Dalbavancin in Bone and Joint Infections: A Systematic Review.
DBV
Gram-positive
Systematic review
arthritis
bone
dalbavancin
joints
osteoarticular infections
osteomyelitis
review
spondylodiscitis
Journal
Pharmaceuticals (Basel, Switzerland)
ISSN: 1424-8247
Titre abrégé: Pharmaceuticals (Basel)
Pays: Switzerland
ID NLM: 101238453
Informations de publication
Date de publication:
15 Jul 2023
15 Jul 2023
Historique:
received:
25
06
2023
revised:
09
07
2023
accepted:
12
07
2023
medline:
29
7
2023
pubmed:
29
7
2023
entrez:
29
7
2023
Statut:
epublish
Résumé
Approved for acute bacterial skin and skin structure infections, dalbavancin (DBV) has gradually acquired over the years a role as an off-label treatment for several infections caused by Gram-positive bacteria even in other anatomical sites. Osteoarticular (OA) infections are one of the most difficult-to-treat infections and, since the absence of recommendations, clinicians use different and heterogenic DBV dosing schedule regimens for the off-label treatment of osteomyelitis, spondylodiscitis, and septic arthritis. Our aim is to systematically review the current literature to describe DBV administration schedules and their outcome in OA infections. According to the 2020 updated PRISMA guidelines, all peer-reviewed articles regarding the use of DBV in OA infections were included. We conducted a literature search on PubMed and Cochrane Controlled Trials. A total of 23 studies and 450 patients were included, prevalently male (144/195, 73.8%) and diabetic (53/163, 32.5%). Overall, 280 (280/388, 72.2%) osteomyelitis, 79 (79/388, 20.4%) spondylodiscitis, and 29 (29/388, 7.5%) septic arthritis were considered. DBV has shown to be effective as a treatment for OA infections. The most favourable outcome was found in patients receiving three doses of DBV and with an adequate surgical management prior to antibiotic treatment. Although a rigorous administration schedule does not exist, DBV is a viable treatment option in the management of OA infections.
Sections du résumé
BACKGROUND
BACKGROUND
Approved for acute bacterial skin and skin structure infections, dalbavancin (DBV) has gradually acquired over the years a role as an off-label treatment for several infections caused by Gram-positive bacteria even in other anatomical sites. Osteoarticular (OA) infections are one of the most difficult-to-treat infections and, since the absence of recommendations, clinicians use different and heterogenic DBV dosing schedule regimens for the off-label treatment of osteomyelitis, spondylodiscitis, and septic arthritis. Our aim is to systematically review the current literature to describe DBV administration schedules and their outcome in OA infections.
METHODS
METHODS
According to the 2020 updated PRISMA guidelines, all peer-reviewed articles regarding the use of DBV in OA infections were included. We conducted a literature search on PubMed and Cochrane Controlled Trials.
RESULTS
RESULTS
A total of 23 studies and 450 patients were included, prevalently male (144/195, 73.8%) and diabetic (53/163, 32.5%). Overall, 280 (280/388, 72.2%) osteomyelitis, 79 (79/388, 20.4%) spondylodiscitis, and 29 (29/388, 7.5%) septic arthritis were considered.
CONCLUSIONS
CONCLUSIONS
DBV has shown to be effective as a treatment for OA infections. The most favourable outcome was found in patients receiving three doses of DBV and with an adequate surgical management prior to antibiotic treatment. Although a rigorous administration schedule does not exist, DBV is a viable treatment option in the management of OA infections.
Identifiants
pubmed: 37513919
pii: ph16071005
doi: 10.3390/ph16071005
pmc: PMC10385685
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Références
Infect Dis Ther. 2022 Feb;11(1):435-449
pubmed: 34913137
Infect Dis Ther. 2019 Jun;8(2):171-184
pubmed: 31054088
Int J Antimicrob Agents. 2020 Dec;56(6):106210
pubmed: 33223119
Diagn Microbiol Infect Dis. 2019 Mar;93(3):213-218
pubmed: 30396697
J Antimicrob Chemother. 2017 Feb;72(2):441-443
pubmed: 28073963
Antimicrob Agents Chemother. 2022 Jun 21;66(6):e0261420
pubmed: 35475634
Plast Reconstr Surg. 2011 Jan;127 Suppl 1:190S-204S
pubmed: 21200291
Antimicrob Agents Chemother. 2021 Mar 1;65(5):
pubmed: 33649108
Infection. 2019 Dec;47(6):1013-1020
pubmed: 31520397
Int J Antimicrob Agents. 2019 Nov;54(5):668-672
pubmed: 31400471
Open Forum Infect Dis. 2021 Dec 18;9(2):ofab589
pubmed: 35071682
Clin Drug Investig. 2021 May;41(5):437-448
pubmed: 33884583
Antibiotics (Basel). 2021 Sep 19;10(9):
pubmed: 34572711
Antimicrob Agents Chemother. 2007 May;51(5):1633-42
pubmed: 17307987
Int J Infect Dis. 2019 Apr;81:128-136
pubmed: 30772469
Chin J Traumatol. 2023 Jul;26(4):228-235
pubmed: 36828768
Expert Rev Anti Infect Ther. 2021 Sep;19(9):1125-1134
pubmed: 33682593
Eur Rev Med Pharmacol Sci. 2019 Apr;23(2 Suppl):258-270
pubmed: 30977893
Pharmaceutics. 2022 Sep 06;14(9):
pubmed: 36145630
BMJ. 2021 Mar 29;372:n71
pubmed: 33782057
Diagn Microbiol Infect Dis. 2016 Aug;85(4):449-51
pubmed: 27241369
Expert Rev Anti Infect Ther. 2022 Jul;20(7):997-1004
pubmed: 35353020
Diagn Microbiol Infect Dis. 2018 Jan;90(1):58-63
pubmed: 29195766
PLoS One. 2021 Nov 29;16(11):e0260539
pubmed: 34843561
Int J Infect Dis. 2019 Apr;81:210-214
pubmed: 30794940
Clin Infect Dis. 2015 Sep 15;61(6):e26-46
pubmed: 26229122
Microbiol Spectr. 2023 Feb 14;11(1):e0238522
pubmed: 36537818
J Med Econ. 2023 Jan-Dec;26(1):463-472
pubmed: 36950932
Clin Pharmacokinet. 2022 Mar;61(3):363-374
pubmed: 34931283
Reumatol Clin (Engl Ed). 2018 Sep - Oct;14(5):301-302
pubmed: 28283311
Am J Case Rep. 2017 Dec 09;18:1315-1319
pubmed: 29222405
Antibiotics (Basel). 2022 Jul 24;11(8):
pubmed: 35892386
J Antimicrob Chemother. 2020 Oct 1;75(10):2717-2722
pubmed: 32457989
J Antimicrob Chemother. 2019 Jan 1;74(1):82-86
pubmed: 30260409
J Clin Pharmacol. 2009 Apr;49(4):465-76
pubmed: 19318696
Eur Rev Med Pharmacol Sci. 2023 Feb;27(3):1222-1238
pubmed: 36808371
J Chemother. 2022 Oct;34(6):360-366
pubmed: 34923922
Infect Dis Clin North Am. 2017 Jun;31(2):325-338
pubmed: 28483044
Open Forum Infect Dis. 2019 Jan 30;6(2):ofz028
pubmed: 30838225
Braz J Infect Dis. 2014 Sep-Oct;18(5):526-34
pubmed: 24698709
Int J Antimicrob Agents. 2013 Sep;42(3):220-5
pubmed: 23880168
Open Forum Infect Dis. 2018 Dec 10;6(1):ofy331
pubmed: 30648126
Antimicrob Agents Chemother. 2019 Apr 25;63(5):
pubmed: 30858217
Diagn Microbiol Infect Dis. 2020 Feb;96(2):114901
pubmed: 31761480
Antibiotics (Basel). 2022 Oct 08;11(10):
pubmed: 36290035
Med Arch. 2020 Jun;74(3):243-245
pubmed: 32801445
Pharmacotherapy. 2020 May;40(5):469-478
pubmed: 32239771
J Infect Chemother. 2022 Mar;28(3):465-468
pubmed: 35016828
Int J Infect Dis. 2005 May;9(3):127-38
pubmed: 15840453
Antimicrob Agents Chemother. 2015 Apr;59(4):1849-55
pubmed: 25561338
Biomedicines. 2021 Sep 22;9(10):
pubmed: 34680409
Enferm Infecc Microbiol Clin (Engl Ed). 2022 Jun-Jul;40(6):296-301
pubmed: 35490091
Antimicrob Steward Healthc Epidemiol. 2022 May 20;2(1):e83
pubmed: 36483361
Antibiotics (Basel). 2021 Oct 24;10(11):
pubmed: 34827234
Saudi Pharm J. 2020 Apr;28(4):460-464
pubmed: 32273805
Drug Des Devel Ther. 2021 Aug 03;15:3349-3378
pubmed: 34376971
Diagn Microbiol Infect Dis. 2013 Mar;75(3):304-7
pubmed: 23357293
Int J Antimicrob Agents. 2020 Sep;56(3):106069
pubmed: 32603683